Verition Fund Management LLC Krystal Biotech, Inc. Transaction History

Verition Fund Management LLC

$17.4 Billion
Q3 2024

A detailed history of Verition Fund Management LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 16,000 shares of KRYS stock, worth $3.05 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

16,000

Previous 17,989 11.06%

Holding current value

$3.05 Million

Previous $3.3 Million 11.93%

% of portfolio

0.02%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $347,478 - $424,969	-1,989 Reduced 11.06%	16,000 $2.91 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $6.71 Million - $8.05 Million	-43,811 Reduced 70.89%	17,989 $3.3 Million
Q1 2024 May 14, 2024	SELL	$108.01 - $179.35 $3.69 Million - $6.13 Million	-34,158 Reduced 35.6%	61,800 $11 Million
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $2.99 Million - $3.99 Million	-31,112 Reduced 24.48%	95,958 $11.9 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $3.83 Million - $4.6 Million	35,338 Added 38.52%	127,070 $14.7 Million
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $150,053 - $249,171	-1,912 Reduced 2.04%	91,732 $10.8 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $947,078 - $1.1 Million	13,083 Added 16.24%	93,644 $7.5 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $815,074 - $1.03 Million	12,909 Added 19.08%	80,561 $6.38 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $837,083 - $1.06 Million	12,908 Added 23.58%	67,652 $4.72 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $1.15 Million - $1.73 Million	23,578 Added 75.65%	54,744 $3.59 Million
Q1 2022 May 13, 2022	SELL	$51.99 - $72.11 $2.34 Million - $3.24 Million	-44,948 Reduced 59.05%	31,166 $2.07 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $400,846 - $888,488	10,069 Added 15.25%	76,114 $5.32 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $2.47 Million - $3.41 Million	47,464 Added 255.44%	66,045 $3.45 Million
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $3.19 Million - $4.19 Million	-51,266 Reduced 73.4%	18,581 $1.26 Million
Q1 2021 May 18, 2021	SELL	$59.42 - $85.46 $457,355 - $657,785	-7,697 Reduced 9.93%	69,847 $5.38 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $874,369 - $1.32 Million	21,515 Added 38.4%	77,544 $4.65 Million
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $394,856 - $507,059	-10,457 Reduced 15.73%	56,029 $2.41 Million
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $722,233 - $1.17 Million	-19,504 Reduced 22.68%	66,486 $2.75 Million
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $2.16 Million - $4.06 Million	61,798 Added 255.45%	85,990 $3.72 Million
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $1.49 Million - $2.94 Million	-45,002 Reduced 65.04%	24,192 $1.34 Million
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $227,207 - $335,707	6,544 Added 10.45%	69,194 $2.4 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $1.7 Million - $2.58 Million	62,650 New	62,650 $2.52 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Account

Verition Fund Management LLC Krystal Biotech, Inc. Transaction History